Page last updated: 2024-12-05

oxolamine

Description Research Excerpts Clinical Trials Roles Classes Pathways Study Profile Bioassays Related Drugs Related Conditions Protein Interactions Research Growth Market Indicators

Description

Oxolamine is an investigational drug that acts as a selective inhibitor of the enzyme monoamine oxidase-B (MAO-B). It has shown potential therapeutic effects in the treatment of Parkinson's disease and other neurodegenerative disorders. Oxolamine's mechanism of action involves the inhibition of MAO-B, which leads to an increase in the levels of dopamine in the brain. Dopamine is a neurotransmitter involved in motor control, mood, and cognition. By increasing dopamine levels, oxolamine may alleviate the symptoms of Parkinson's disease, such as tremors, rigidity, and bradykinesia. The compound is currently in preclinical development, and its potential therapeutic benefits and safety profile are still being investigated.'

oxolamine: RN given refers to parent cpd; structure [Medical Subject Headings (MeSH), National Library of Medicine, extracted Dec-2023]

Cross-References

ID SourceID
PubMed CID13738
CHEMBL ID1620875
CHEBI ID94607
SCHEMBL ID893333
MeSH IDM0052842

Synonyms (66)

Synonym
ossolamina
90bea145gy ,
5-(2-dietilaminoetil)-3-fenil-1,2,4-oxadiazolo
ec 213-493-4
oxolamina
oxolaminum
unii-90bea145gy
BRD-K42596464-048-03-6
oxolamine
959-14-8
oxolev
brn 0527181
af 438
oxolamina [italian]
5-(2-dietilaminoetil)-3-fenil-1,2,4-oxadiazolo [italian]
einecs 213-493-4
oxolev a
n,n-diethyl-3-phenyl-1,2,4-oxadiazole-5-ethanamine
5-(2-diethylaminoethyl)-3-phenyl-1,2,4-oxadiazole
1,2,4-oxadiazole, 5-(2-(diethylamino)ethyl)-3-phenyl-
oxolamine [inn:dcf]
683 m
oxolamina [inn-spanish]
ossolamina [dcit]
jatan
3-phenyl-5-(beta-diethylaminoethyl)-1,2,4-oxodiazole
oxolaminum [inn-latin]
NCGC00179449-01
oxolamine (inn)
oksalamin (tn)
D07387
BSPBIO_000751
BPBIO1_000827
PRESTWICK3_000826
n,n-diethyl-2-(3-phenyl-1,2,4-oxadiazol-5-yl)ethanamine 2-hydroxy-1,2,3-propanetricarboxylate
n,n-diethyl-2-(3-phenyl-1,2,4-oxadiazol-5-yl)ethanamine
PRESTWICK1_000826
SPBIO_002672
PRESTWICK0_000826
PRESTWICK2_000826
af-438 [as citrate]
CHEMBL1620875
skf 9976 [as citrate]
oksalamin
skf 9976 free base
af-438 free base
skf-9976 free base
SCHEMBL893333
oxolamine [mi]
oxolamine [inn]
oxolamine [who-dd]
oxolamine [mart.]
1,2,4-oxadiazole-5-ethanamine, n,n-diethyl-3-phenyl-
3-phenyl-5-(.beta.-diethylaminoethyl)-1,2,4-oxodiazole
IDCHQQSVJAAUQQ-UHFFFAOYSA-N
DTXSID5023403
AKOS027381579
CHEBI:94607
SBI-0207016.P001
FT-0748644
Q576684
n,n-diethyl-2-(3-phenyl-1,2,4-oxadiazol-5-yl)ethan-1-amine
DB13216
oxadiazole; 683m
EN300-22203695
diethyl[2-(3-phenyl-1,2,4-oxadiazol-5-yl)ethyl]amine

Research Excerpts

Dosage Studied

ExcerptRelevanceReference
"One of the principal uses of microencapsulation for pharmaceuticals has been the preparation of sustained-release dosage forms which have been usually presented in the form of a suspension or gel."( Sustained-release dosage form of oxolamine citrate: preparation and release kinetics.
Güneri, T; Kendirci, A; Kirilmaz, L,
)
0.41
[information is derived through text-mining from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Drug Classes (2)

ClassDescription
oxadiazole
ring assemblyTwo or more cyclic systems (single rings or fused systems) which are directly joined to each other by double or single bonds are named ring assemblies when the number of such direct ring junctions is one less than the number of cyclic systems involved.
[compound class information is derived from Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res]

Bioassays (2)

Assay IDTitleYearJournalArticle
AID588220Literature-mined public compounds from Kruhlak et al phospholipidosis modelling dataset2008Toxicology mechanisms and methods, , Volume: 18, Issue:2-3
Development of a phospholipidosis database and predictive quantitative structure-activity relationship (QSAR) models.
AID1159607Screen for inhibitors of RMI FANCM (MM2) intereaction2016Journal of biomolecular screening, Jul, Volume: 21, Issue:6
A High-Throughput Screening Strategy to Identify Protein-Protein Interaction Inhibitors That Block the Fanconi Anemia DNA Repair Pathway.
[information is prepared from bioassay data collected from National Library of Medicine (NLM), extracted Dec-2023]

Research

Studies (40)

TimeframeStudies, This Drug (%)All Drugs %
pre-199035 (87.50)18.7374
1990's0 (0.00)18.2507
2000's4 (10.00)29.6817
2010's1 (2.50)24.3611
2020's0 (0.00)2.80
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Market Indicators

Research Demand Index: 50.14

According to the monthly volume, diversity, and competition of internet searches for this compound, as well the volume and growth of publications, there is estimated to be very strong demand-to-supply ratio for research on this compound.

MetricThis Compound (vs All)
Research Demand Index50.14 (24.57)
Research Supply Index3.87 (2.92)
Research Growth Index4.06 (4.65)
Search Engine Demand Index80.25 (26.88)
Search Engine Supply Index2.06 (0.95)

This Compound (50.14)

All Compounds (24.57)

Study Types

Publication TypeThis drug (%)All Drugs (%)
Trials2 (4.44%)5.53%
Reviews0 (0.00%)6.00%
Case Studies1 (2.22%)4.05%
Observational0 (0.00%)0.25%
Other42 (93.33%)84.16%
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]